Elisa Tassinari
About
Elisa Tassinari is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery.
According to data from OpenAlex, Elisa Tassinari has authored 34 papers receiving a total of 457 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 13 papers in Surgery. Recurrent topics in Elisa Tassinari's work include Cancer Immunotherapy and Biomarkers (13 papers), Bladder and Urothelial Cancer Treatments (10 papers) and Renal cell carcinoma treatment (9 papers). Elisa Tassinari is often cited by papers focused on Cancer Immunotherapy and Biomarkers (13 papers), Bladder and Urothelial Cancer Treatments (10 papers) and Renal cell carcinoma treatment (9 papers). Elisa Tassinari collaborates with scholars based in Italy, Spain and United States. Elisa Tassinari's co-authors include Francesco Massari, Andrea Marchetti, Matteo Rosellini, Veronica Mollica, Alessandro Rizzo, Matteo Santoni, Valentina Tateo, Raffaella Massafra, Raffaele De Luca and Fernando Sabino Marques Monteiro and has published in prestigious journals such as International Journal of Molecular Sciences, Molecules and European Urology.
In The Last Decade
Elisa Tassinari
29 papers receiving 455 citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Elisa Tassinari Italy | 8 | 217 | 205 | 145 | 93 | 84 | 34 | 457 | ||
| Mariachiara Santorsola Italy | 13 | 218 1.0× | 92 0.4× | 121 0.8× | 87 0.9× | 85 1.0× | 45 | 428 | ||
| Jianfei Zhu China | 12 | 145 0.7× | 185 0.9× | 215 1.5× | 161 1.7× | 82 1.0× | 41 | 499 | ||
| Yanmeng Li China | 13 | 139 0.6× | 143 0.7× | 186 1.3× | 150 1.6× | 59 0.7× | 43 | 496 | ||
| Lingzhi Hong United States | 12 | 216 1.0× | 238 1.2× | 213 1.5× | 115 1.2× | 45 0.5× | 28 | 487 | ||
| Elisa Giommoni Italy | 14 | 314 1.4× | 180 0.9× | 158 1.1× | 138 1.5× | 66 0.8× | 45 | 527 | ||
| Norifumi Iseda Japan | 13 | 171 0.8× | 159 0.8× | 147 1.0× | 180 1.9× | 125 1.5× | 54 | 498 | ||
| Andrea Pretta Italy | 12 | 272 1.3× | 102 0.5× | 182 1.3× | 139 1.5× | 61 0.7× | 47 | 478 | ||
| Daniele Lavacchi Italy | 12 | 303 1.4× | 184 0.9× | 124 0.9× | 85 0.9× | 75 0.9× | 46 | 476 | ||
| Depei Huang China | 10 | 340 1.6× | 197 1.0× | 90 0.6× | 81 0.9× | 51 0.6× | 24 | 482 | ||
| Tahir Qayyum United Kingdom | 11 | 144 0.7× | 116 0.6× | 137 0.9× | 93 1.0× | 55 0.7× | 20 | 386 |
Countries citing papers authored by Elisa Tassinari
Since
Specialization
Citations
This map shows the geographic impact of Elisa Tassinari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elisa Tassinari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elisa Tassinari more than expected).
Fields of papers citing papers by Elisa Tassinari
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Elisa Tassinari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elisa Tassinari. The network helps show where Elisa Tassinari may publish in the future.
Co-authorship network of co-authors of Elisa Tassinari
This figure shows the co-authorship network connecting the top 25 collaborators of Elisa Tassinari. A scholar is included among the top collaborators of Elisa Tassinari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elisa Tassinari. Elisa Tassinari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Rosellini, Matteo, Veronica Mollica, Andrea Marchetti, et al.. (2025). Insights into the impact of chromosome 3p mutations in advanced renal cell carcinoma treated with immune-based combinations or targeted therapy: A single-center experience. Pathology - Research and Practice. 270. 155964–155964.
2.
Tassinari, Elisa & Andrea Milelli. (2025). Leveraging targeted kinase degradation as a novel therapeutic strategy for Alzheimer's disease. RSC Medicinal Chemistry. 16(12). 5862–5872.
3.
Tassinari, Elisa, Andrea Marchetti, Matteo Rosellini, et al.. (2025). Current androgen receptor antagonists under investigation for resistant prostate cancer: progress and challenges. Expert Review of Anticancer Therapy. 25(5). 457–470.
4.
Tassinari, Elisa, Manuela Loi, Elisabetta Ciani, et al.. (2024). First in Class Dual Non-ATP-Competitive Glycogen Synthase Kinase 3β/Histone Deacetylase Inhibitors as a Potential Therapeutic to Treat Alzheimer’s Disease. ACS Chemical Neuroscience. 15(11). 2099–2111.
5.
Greco, Giulia, Elisa Tassinari, Christian Bergamini, et al.. (2024). Integrating a quinone substructure into histone deacetylase inhibitors to cope with Alzheimer's disease and cancer. RSC Medicinal Chemistry. 15(6). 2045–2062.
6.
Mollica, Veronica, Andrea Marchetti, Cristina Nanni, et al.. (2024). A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single-center experience. ESMO Open. 9(5). 103448–103448.
7.
Casadio, Chiara, Matteo Rosellini, Andrea Marchetti, et al.. (2024). Novel Immune Checkpoint Inhibitor Targets in Advanced or Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives. Journal of Clinical Medicine. 13(19). 5738–5738.
8.
Tassinari, Elisa, Andrea Marchetti, Matteo Rosellini, et al.. (2024). State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes. Human Vaccines & Immunotherapeutics. 21(1). 2440165–2440165.
9.
Tassinari, Elisa, Francesco Porta, Valerio Di Scioscio, et al.. (2023). Metabolic pseudoprogression in a patient with metastatic KIT exon 11 GIST after 1 month of first-line imatinib: a case report. Frontiers in Oncology. 13. 1310452–1310452.
10.
Cozza, Giorgio, Monica Rossetto, Manuela Cervelli, et al.. (2023). From Monoamine Oxidase Inhibition to Antiproliferative Activity: New Biological Perspectives for Polyamine Analogs. Molecules. 28(17). 6329–6329.
11.
Mollica, Veronica, Alessandro Rizzo, Andrea Marchetti, et al.. (2023). The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study. Clinical and Experimental Medicine. 23(8). 5039–5049.
12.
Rizzo, Alessandro, Veronica Mollica, Valentina Tateo, et al.. (2023). Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study. Cancer Immunology Immunotherapy. 72(6). 1381–1394.
13.
Santoni, Matteo, Alessandro Rizzo, Jakub Kucharz, et al.. (2023). Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. Cancer Immunology Immunotherapy. 72(6). 1365–1379.
14.
Rosellini, Matteo, Elisa Tassinari, Andrea Marchetti, Veronica Mollica, & Francesco Massari. (2023). Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial. European Urology. 85(1). 97–98.
15.
Marchetti, Andrea, Matteo Rosellini, Elisa Tassinari, et al.. (2022). PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What’s Now, What’s New, and What’s Coming?. Cancers. 14(4). 907–907.
16.
Rizzo, Alessandro, Veronica Mollica, Andrea Marchetti, et al.. (2022). Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study. Cancers. 14(17). 4142–4142.
17.
Mollica, Veronica, Elisa Tassinari, Andrea Marchetti, et al.. (2022). Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw. Current Oncology. 29(3). 1709–1722.
18.
Mollica, Veronica, Dario de Biase, Francesca Giunchi, et al.. (2022). A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy.. Pathology - Research and Practice. 236. 153983–153983.
19.
Tassinari, Elisa, et al.. (2022). Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy. Cancer Management and Research. Volume 14. 1945–1960.
20.
Marchetti, Andrea, Matteo Rosellini, Veronica Mollica, et al.. (2021). The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What’s the Story Morning Glory?. International Journal of Molecular Sciences. 22(12). 6237–6237.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Mariachiara Santorsola Breakdown of academic impact, for papers by Jianfei Zhu Breakdown of academic impact, for papers by Yanmeng Li Breakdown of academic impact, for papers by Lingzhi Hong Breakdown of academic impact, for papers by Elisa Giommoni Breakdown of academic impact, for papers by Norifumi Iseda Breakdown of academic impact, for papers by Andrea Pretta Breakdown of academic impact, for papers by Daniele Lavacchi Breakdown of academic impact, for papers by Depei Huang Breakdown of academic impact, for papers by Tahir Qayyum